FDA crackdown on unapproved GLP-1 weight-loss drugs

The U.S. FDA warned patients and providers about serious health risks from unapproved and compounded GLP-1 weight-loss drugs, detailing hospitalizations and adverse events reported for compounded semaglutide and tirzepatide. Regulators noted unsafe formulations, incorrect salt forms, contamination risks, and improper labeling, alongside import alerts targeting noncompliant manufacturers to protect the domestic supply chain. In business news, Hims & Hers expanded its international footprint by acquiring Australia’s digital health platform Eucalyptus, absorbing the Pilot men’s telehealth brand to offer branded GLP-1 weight-loss drugs and related treatments in Australia. The rollout will integrate Pilot clinicians into Hims’ platform, with plans to launch a women’s health segment later in Australia via the Juniper brand, as the company pursues a $6.5 billion revenue target by 2030. APAC digital-health consolidation is accelerating as Hims reports a 21% year-over-year rise in monthly revenue per subscriber, even as gross margins remain a challenge. The coverage of Hims’ Australia push is echoed across industry outlets, underscoring a global push into GLP-1 therapies despite regulatory crackdowns at the FDA.